Comparative Pharmacology
Head-to-head clinical analysis: LENALIDOMIDE versus REVLIMID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LENALIDOMIDE versus REVLIMID.
LENALIDOMIDE vs REVLIMID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Immunomodulatory agent with anti-angiogenic and anti-proliferative properties; alters cytokine production, enhances T-cell and NK-cell activity, inhibits tumor angiogenesis, and directly induces apoptosis in tumor cells.
Revlimid (lenalidomide) is an immunomodulatory agent with antiangiogenic and antineoplastic properties. It inhibits tumor necrosis factor-alpha, stimulates T-cell proliferation and IL-2 production, and inhibits angiogenesis by blocking VEGF and bFGF. It also modulates the ubiquitin E3 ligase cereblon, leading to degradation of transcription factors Ikaros and Aiolos, which results in direct tumor cell apoptosis and enhanced immune function.
10 mg orally once daily on days 1-21 of 28-day cycle for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes; 25 mg orally once daily on days 1-21 of 28-day cycle for relapsed/refractory multiple myeloma.
5-10 mg orally once daily for 21 days of a 28-day cycle; dose depends on indication (e.g., 10 mg for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes).
None Documented
Clinical Note
moderateLenalidomide + Digitoxin
"Lenalidomide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateLenalidomide + Deslanoside
"Lenalidomide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateLenalidomide + Acetyldigitoxin
"Lenalidomide may decrease the cardiotoxic activities of Acetyldigitoxin."
Clinical Note
moderateLenalidomide + Ouabain
"Lenalidomide may decrease the cardiotoxic activities of Ouabain."
None Documented
Terminal half-life ~3 hours (range 2-5 h) in multiple myeloma patients; prolongation in renal impairment requires dose adjustment.
Terminal elimination half-life of approximately 3-5 hours in patients with normal renal function. Half-life is prolonged in renal impairment (up to 9 hours in severe impairment).
Renal: ~82% unchanged; fecal <5%; biliary negligible.
Primarily renal excretion as unchanged drug (approximately 67% of the dose in urine over 24 hours) with minor fecal elimination (<4%).
Category C
Category C
Immunomodulatory Agent
Immunomodulatory Agent